Research
Hormonal
There were no reported hospitalizations from severe hypoglycemia or diabetic ketoacidosis in the treated group.
The safety profile suggests that tirzepatide may be a safe option for managing T1D in this population.
StrongSupportsmedium confidence
There were no reported hospitalizations from severe hypoglycemia or diabetic ketoacidosis.
Why this rating
Based on study design from abstract.
Source
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Satish K. Garg et al. · Diabetes Technology & Therapeutics · 2024
DOI 10.1089/dia.2024.0050
cohort · n=62Cited 57×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →